{"entity":{"id":"nct07599995","kind":"trial","name":"Gemcitabine-Cisplatin Plus Envafolimab in Resectable Biliary Tract Malignancies","aka":["GENE"],"tldr":"A phase 2 trial of envafolimab, gemcitabine and cisplatin in gallbladder cancer and other biliary tract cancers, run by Sir Run Run Shaw Hospital, not yet recruiting.","summary":"Gemcitabine-Cisplatin Plus Envafolimab in Resectable Biliary Tract Malignancies is a phase 2 interventional study registered as NCT07599995 by Sir Run Run Shaw Hospital, with a registry enrolment figure of 34 participants, started 2026-05-30 and due to reach its primary completion in 2028-03-30. Interventions recorded: Neoadjuvant therapy followed by surgery. Conditions listed: Biliary Tract Cancer. No results are recorded here; the registry entry is the source.","status":"planned","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT07599995","url":"https://clinicaltrials.gov/study/NCT07599995"}],"tags":["ctgov-ingest","gallbladder-deep-dive"],"related":[],"cancers":["gallbladder","cholangiocarcinoma","biliary-tract-cancer"],"sections":[],"technologies":["checkpoint-inhibitor","cytotoxic-chemotherapy","platinum"],"targets":[],"drugs":["envafolimab","gemcitabine","cisplatin"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07599995","phase":"2","setting":"The Efficacy and Safety of Gemcitabine-Cisplatin Plus Envafolimab as Neoadjuvant Therapy in Resectable Biliary Tract Malignancies at High Risk of Recurrence","sponsor":"Sir Run Run Shaw Hospital","enrolled":34,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07599995/","neighbours":{"cancer":[{"id":"biliary-tract-cancer","kind":"cancer","name":"Biliary tract cancer (all types)","route":"/cancers/biliary-tract-cancer/"},{"id":"cholangiocarcinoma","kind":"cancer","name":"Biliary tract cancer (cholangiocarcinoma)","route":"/cancers/cholangiocarcinoma/"},{"id":"gallbladder","kind":"cancer","name":"Gallbladder cancer","route":"/cancers/gallbladder/"}],"technology":[{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"},{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"},{"id":"platinum","kind":"technology","name":"Platinum agents","route":"/technologies/platinum/"}],"drug":[{"id":"cisplatin","kind":"drug","name":"Cisplatin","route":"/drugs/cisplatin/"},{"id":"envafolimab","kind":"drug","name":"Envafolimab","route":"/drugs/envafolimab/"},{"id":"gemcitabine","kind":"drug","name":"Gemcitabine","route":"/drugs/gemcitabine/"}],"term":[{"id":"gallbladder-cancer-in-biliary-trials","kind":"term","name":"Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups)","route":"/terms/gallbladder-cancer-in-biliary-trials/"}]}}